Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2018-11-29
Target enrollment:
Participant gender:
Summary
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered
daily over a 6-week dosing period in subjects with refractory wet age-related macular
degeneration (wAMD).